Kdigo guidelines steroid resistant nephrotic syndrome

Results  Treatment with paricalcitol reduced parathyroid hormone levels within 4 weeks and maintained levels within the normal range throughout the study duration. At 48 weeks, the change in left ventricular mass index did not differ between treatment groups (paricalcitol group, g/m [95% CI, − to g/m ] vs placebo group, − g/m [95% CI, − to g/m ]). Doppler measures of diastolic function including peak early diastolic lateral mitral annular tissue velocity (paricalcitol group, − cm/s [95% CI, − to cm/s] vs placebo group, − cm/s [95% CI, − to cm/s]) also did not differ. Episodes of hypercalcemia were more frequent in the paricalcitol group compared with the placebo group.

Endocrine Treatment of Transsexual Persons
Last updated :         2009
Published :             J Clin Endocrinol Metab   2009; 94:3132–3154
Sponsor:               Endocrine Society, European Society of Endocrinology, European Society for Paediatric Endocrinology, Lawson Wilkins Pediatric Endocrine Society, and World Professional Association for Transgender Health
Website :              http://-/guidelines/Current-Clinical-Practice-

AB - The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline on glomerulonephritis (GN) is intended to assist the practitioner caring for patients with GN. Two chapters of this guideline focus specifically on nephrotic syndrome in children. Guideline development followed a thorough evidence review, and management recommendations and suggestions were based on the best available evidence. Critical appraisal of the quality of evidence and strength of recommendations followed the Grades of Recommendation Assessment, Development and Evaluation (GRADE) approach. Chapters 3 and 4 of the guideline focus on the management of nephrotic syndrome in children aged 1-18 years. Guideline recommendations for children who have steroid-sensitive nephrotic syndrome (SNSS), defined by their response to corticosteroid therapy with complete remission, are addressed here. Recommendations for those with steroid-resistant nephrotic syndrome (SRNS) (., do not achieve complete remission) are discussed in the companion article. Limitations of the evidence, including the paucity of large-scale randomized controlled trials, are discussed. This article provides a short description of the KDIGO process, the guideline recommendations for treatment of SSNS in children and a brief review of relevant treatment trials related to each recommendation.

Kdigo guidelines steroid resistant nephrotic syndrome

kdigo guidelines steroid resistant nephrotic syndrome


kdigo guidelines steroid resistant nephrotic syndromekdigo guidelines steroid resistant nephrotic syndromekdigo guidelines steroid resistant nephrotic syndrome